I will be back and posting as soon as current projects are completed........
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
its been awhile , but I believe the dose was to be delivered throughout the day as opposed to a single shot...5 mists per. I would prefer the inhaler ......... price shouldnt be that big of an issue as they started by marketing to and manufacturing in Ecuador I believe it was... and as far as the US .... value is based on convenience.
Generex Biotechnology to Make Presentations at The Obesity Society Annual Scientific Meeting
WORCESTER, Mass., Oct. 22, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will be making two poster presentations at The Obesity Society Annual Scientific Meeting 2007 in New Orleans, Louisiana, October 20-24, 2007 (http://www.obesity.org/annualmeeting07).
The first abstract features Glucose RapidSpray(tm), the Company's proprietary glucose spray product:
"Glucose RapidSpray(tm): A New Device to Control Neuroglycopenia and Consequent Request for Food," by Professor Paolo Pozzilli, University Campus Bio-Medico, Rome, Italy, with Antonio Picardi, Manon Yeganeh Merola, Maria Altomare, Natalia Visalli, Elisa Cipponeri and Chiara Guglielmi.
The second abstract features the Company's proprietary metformin chewing gum:
"Metformin Gum: An Alternative Method for Delivery of Biguanides," by Doctors Jaime Guevara-Aguirre, David Saldarreaga, Marco Guevara-Aguirre and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador.
Celebrating its 25th anniversary this year, The Obesity Society aims to understand, prevent, and treat obesity. Seeking to improve the lives of those with obesity, The Obesity Society promotes research, education, and advocacy in the field of obesity.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. In June, 2007 the Company announced the commencement of a global Phase III clinical trial of Generex Oral-lyn(tm) in the third quarter of 2007 with patient dosing to commence before yearend. For more information, visit the Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
CONTACT: For Generex:
CEOcast, Inc.
Andrew Hellman
(212) 732-4300
American Capital Ventures, Inc.
Craig Kulman
(305) 918-7000
no volume... wide spread. .18x .25
Greater China Media & Entertainment Corp. Subsidiary Arranges 2007 China Canon Exhibition Tennis Tournament
BEIJING, Oct. 18 /Xinhua-PRNewswire/ -- Greater China Media & Entertainment Corporation (OTC Bulletin Board: GCME; 'GCME'), an integrated professional media and entertainment company, reports that its subsidiary, Racemind HuaDing, provided public relations services for the 2007 China Canon Exhibition Tennis Tournament sponsored by Beijing Dentsu Advertising Co., Ltd (Dentsu). The projected contract value for GCME is US$118,700. The event was held at the Beijing Guang Cai Stadium from September 2 to September 23.
Beijing Dentsu was established by three top performing companies in 1994, including the world-renowned Japanese advertising group Dentsu. Its core businesses are integrated branding services, media service, event marketing and sales promotions. As its public services agent, Racemind HuaDing executed on-spot administration, stage building and AV operation for the event.
According to Jake Wei, Chairman and CEO of Greater China Media & Entertainment, 'Racemind HuaDing's team of professionals offered exceptionally efficient services and products during this event. Working with Microsoft China has helped us penetrate the public relations market. We'll continue to provide our clients and shareholders with improved ongoing efforts'.
About Greater China Media and Entertainment Corporation:
Greater China Media & Entertainment Corp. ('GCME' or the 'Company') is an integrated professional media and entertainment company covering various areas including film and TV program production, management, promotion and distribution. The Company maintains its own film and television production center, promotion agency, audio-visual distribution company, digital network company, talent agency, and sales and advertising agency as a result of recent joint ventures. With its broad range of media and entertainment talents, the company is capable of making films, TV programs and related projects on a large scale.
Joint Ventures:
In June 2006, GCME signed and closed an Acquisition Agreement with Triumph Research Limited, a BVI company and party to a Joint Venture Agreement with Beijing Tangde International Film and Culture Co., Ltd. (Tangde), a Chinese company focused on producing TV programming and movies. The Company's public relations, media strategy, consulting and event management joint venture, Beijing Racemind HuaDing International Marketing Consultants Limited (Racemind HuaDing) was organized in 2006 and approved for business by the Beijing Administration for Industry in May 2007. The Company also signed an agreement with Beijing Star King Talent Agency to form a joint venture to carry on business as a talent agency.
Recent milestones:
Movie and television series production and distribution
-- GCME signed stars appeared in the 'Invincible' TV Series.
-- Signed a production and distribution deal with Mega Vision Productions
Limited for the new 'Tough Guy' movie. 'Tough Guy' completed shooting
recently.
-- Took delivery of its first script for its 'True Love' television
series to be directed by famed director Wong Jing.
-- Signed a production and distribution deal for its 'Poor Dad, Rich Dad'
television series with HuaYi Union Cultural Media Investment Company
Limited. 'Poor Dad, Rich Dad' wrapped up shooting recently.
Racemind HuaDing
-- Signed public relations services agreement with CCTV for the 2007
Asia-Pacific Robot Contest.
-- Signed service agreement with Siemens LTD. China's Transportation
Systems group.
-- Provided public relations services to Beijing ShiChuang Environmental
Protection Development Co., Ltd.
-- Organized Johnson & Johnson 'Family Event'.
-- Selected by Microsoft China as an approved public relations vendor,
and arranged conferences, new product press releases and events.
For more information please visit the Company website at http://www.greaterchinamedia.com
Forward-looking statements:
This report contains 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this report are forward-looking statements. Forward-looking statements involve risks and uncertainties including, but not limited to, economic and political factors; developments of the Chinese and North American markets and changes in regulatory matters; our business strategies and future plans of operations; the market acceptance and amount of sales of our products and services; our historical losses; the competitive environment within the industries in which we compete; and our ability to raise additional capital, currently needed for expansion.
The Company cautions that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements due to several important factors.
For more information, please contact:
Greater China Media & Entertainment Corp.
Jake Wei
Phone: +86-10-5921-2333
SOURCE Greater China Media & Entertainment Corporation
Source: PR Newswire (October 18, 2007 - 1:44 PM EDT)
Generex Biotechnology Announces Product Licensing and Distribution Agreement for Generex Oral-lyn in South Africa
Adcock Ingram Healthcare (Pty) Ltd. to Market and Distribute Generex Oral-Lyn in South Africa and Six Other Neighboring Countries
WORCESTER, Mass., Oct. 18, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has entered into an exclusive Product Licensing & Distribution agreement with Adcock Ingram Limited and Adcock Ingram Healthcare (Pty) Ltd. (www.adcock.co.za) for the marketing, distribution, and sale of Generex Oral-lyn, the Company's proprietary oral insulin spray product, in South Africa and 6 other neighboring countries: Lesotho, Swaziland, Botswana, Namibia, Mozambique, and Zimbabwe.
Adcock Ingram, part of the Tiger Brands Group, is a leading South African pharmaceutical company with an 11.4% share of the private healthcare market. Adcock Ingram has an extensive range of prescription, generic, and over-the-counter products and also provides life saving hospital equipment and diagnostic products and services.
According to the latest edition of the Diabetes Atlas 2007, the prevalence of diabetes in South Africa is 4.5% while 8% of the population suffers from impaired glucose tolerance (IGT). The prevalence of diabetes in each of the other countries is: Lesotho, 4%; Swaziland, 3.8%; Botswana, 4.2%; Namibia, 4%; Mozambique, 3.1%; and Zimbabwe, 3.6%. The average prevalence of IGT in those six countries is 7.78%.
"We are delighted to have licensed Generex Oral-lyn to Adcock Ingram, a well-established and brand name entity, to advance the commercialization of Generex Oral-lyn in South Africa," said Anna Gluskin, Generex's President & Chief Executive Officer. "The alliance is important to the Company as Adcock Ingram brings a vast knowledge of the local market and also the treatment of diabetes. More so, it represents another significant market that Generex has been able to procure to treat those living with diabetes."
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. In June, 2007 the Company announced the commencement of a global Phase III clinical trial of Generex Oral-lyn(tm) in the third quarter of 2007 with patient dosing to commence before yearend. For more information, visit the Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
CONTACT: For Generex:
American Capital Ventures, Inc.
Craig Kulman
305-918-7000
CEOcast, Inc.
Andrew Hellman
212-732-4300
1.50 has been fair market value for some time now... havent figured in the S-8 from Aug... as I havent been in GNBT since the last run from 1.26 to 2.14. Just following and watching.
For some strange reason I have never added GNBT to my favorites...hmmm
Been following and playing since 05 when I first started loading in the .60-.1.15 range..... made 06 a great year to start with.
Generex Biotechnology Appoints Leading Contract Research Organization to Manage Global Phase III Trials For Generex Oral-lyn
Company Also Selects Other Key Service Providers to Support Upcoming Site Selection and Patient Enrollment
WORCESTER, Mass., Oct 16, 2007 (PrimeNewswire via COMTEX) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has entered into a number of key service agreements for its global Phase III trials for Generex Oral-lyn, its proprietary oral insulin spray product. Generex has selected PSI-CRO AG Clinical Research Services ("PSI") (www.psi-cro.com), a leading contract drug development company to serve as the company's global clinical research organization (CRO) to provide full-service CRO services with 600-full-time staff in Europe and North America.
Another key service provider selected and engaged by the Company is Nextrials, Inc. (www.nextrials.com), which will be responsible for providing Electronic Data Capture, randomization, and data management services. Nextrials is an innovative, award-winning, leader in Web-based software solutions for the clinical research industry. Generex has also entered into an agreement with eResearchTechnology, Inc. (Nasdaq:ERES) (www.ert.com), a market leader in providing centralized electrocardiographic (diagnostic) and cardiac safety services, to supply equipment and provide central ECG services for the Company's Phase III trial. Negotiations with other key service providers and suppliers are ongoing and expected to be completed very soon.
The Company has procured each of these service providers through the efforts of OSMOS Clinical Research, Inc. (www.osmos.us) of San Francisco, California, which Generex engaged earlier this year to assist the Company with the global project management of the Phase III clinical trial.
The Phase III global multi-center clinical study, where enrollment is anticipated to commence shortly, is expected to include 750 patients with Type-1 diabetes mellitus. The primary objective of the study is to compare the efficacy of Generex Oral-lyn and the RapidMist(tm) Diabetes Management Sytem with that of standard regular injectable human insulin therapy as measured by HbA1c in patients with Type-1 diabetes mellitus.
"We are pleased at the progress the Company has made in securing quality service providers as we prepare to announce trial site locations and commence enrollment," said Anna Gluskin, Generex's President and Chief Executive Officer. "We believe this study will demonstrate the success that other Type-1 and Type-2 patients have already experienced internationally and will pave the way for commercialization of Generex Oral-lyn in North America."
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: Generex Biotechnology Corp.
By Staff
CONTACT: Generex Biotechnology Corporation
Shayne Gilliatt
800-391-6755
416-364-2551
CEOcast, Inc.
Andrew Hellman
212-732-4300
Generex Biotechnology Provides Middle Eastern Master Licensee Update On Generex Oral-lyn Regulatory Filings
Leading Healthcare Products Distributor Submits Dossier in Five Countries
WORCESTER, Mass., Oct 15, 2007 (PrimeNewswire via COMTEX) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today an update from its Middle Eastern master licensee, Leosons General Trading Company, a leading distributor of North American healthcare products in the region, on the status of regulatory filings for Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product.
Leosons has filed submissions of the Generex Oral-lyn dossier with regulatory agencies in Kuwait, Qatar, Jordan, Yemen, and the United Arab Emirates. The objective of these submissions is to procure requisite governmental approvals for the importation, marketing, distribution, and sale of Generex Oral-lyn in those jurisdictions.
According to the International Diabetes Federation, the UAE has the second highest incidence of diabetes in the world, affecting 70% of the population. Other countries in the region also have significant incidences of diabetes, with Saudi Arabia ranked third, Bahrain fourth, Kuwait fifth, and Oman sixth. Leosons, based in the UAE, has responsibility for the procurement of all Middle Eastern governmental approvals for the importation, marketing, distribution, and sale of Generex Oral-lyn. Following receipt of approvals, Leosons will market, distribute, and sell the product through its extensive distribution networks in the region. Leosons will, at its sole expense, design and implement plans for the education and training of patients and physicians in the region in respect of the Company's RapidMist(tm) Diabetes Management System and the use of Generex Oral-lyn. Leosons will also be obligated to achieve minimum quarterly sales of the product.
"We are pleased about the progress being made by our master licensee in the Middle East," says Anna Gluskin, Generex's President and Chief Executive Officer. "It reflects the quality of the Company's Generex Oral-lyn dossier that Leosons' review determined that the dossier meets all the necessary requirements for the Middle Eastern regulatory agencies. We believe Generex Oral-lyn will address a major unmet medical need in the region for its large population living with diabetes."
About Leosons
Leosons is a 25-year-old private multinational operating company in the Middle East focusing on the pharmaceutical and healthcare industry. Leosons distributes 15 healthcare-related products which are considered category leaders.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. In June, 2007 the Company announced the commencement of a global Phase III clinical trial of Generex Oral-lyn(tm) in the third quarter of 2007 with patient dosing to commence before yearend. For more information, visit the Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: Generex Biotechnology Corp.
By Staff
CONTACT: For Generex:
American Capital Ventures, Inc.
Craig Kulman
(305) 918-7000
CEOcast, Inc.
Andrew Hellman
(212) 732-4300
Anyone listen to the meeting?
Interesting developments... share holders set a conference call as the company moves into a LOI.
Todd N.Tkachuk, President was in attendance, as well as several others holding +million shares.
Share holders offered to help bring company current:
" (C) upon close of the transactions, the Company shall have no more than $170,000 in outstanding liabilities. "
Offer stands if said LOI isn't viable.
Agreement to see if LOI comes to fruition based on:
"(A) the Company, the Acquisition Group, and persons affiliated with the Acquisition Group are to complete these negotiations for the prospective definitive agreements within 45 days from the date at which the Letter of Intent is executed; "
before any further actions.
Hi Rover az good to see you on the board...
its beautiful....
Frank Dileo Named CEO of ValCom; Formerly Michael Jackson's Manager
ValCom, Inc. (PINKSHEETS: VLCO) announced today the appointment of Mr. Frank Dileo, Michael Jackson's former manager and entertainment industry veteran, to serve as the company's new President and Chief Executive Officer. Mr. Dileo replaces Mr. Vince Vellardita who will remain as Chairman of the Board.
"I am thrilled to have a veteran of Mr. Dileo's expertise and experiences join the ValCom team," stated Mr. Vellardita, former President and CEO of ValCom. We look forward to Mr. Dileo taking charge and implementing the company's business plan. Mr. Dileo will be an asset to the company and bring shareholder value to the stakeholders of the company".
Mr. Dileo said, "I am very excited to lead current management in taking ValCom to the top of its industry. Opportunities like this do not come along very often."
About Mr. Dileo:
Mr. Dileo began his music industry career as a sales representative and promotion executive for CBS Records in 1968. His success continued in the 70s while working promotion stints at RCA Records, and then at country music powerhouse Monument Records in Nashville. In 1979, Frank joined Epic Records in New York as Vice President of National Promotion where the legend began. Overseeing a staff of 65 people and a multi-million dollar budget, Frank helped guide Epic Records from a small 65 million dollar company to a 250 million dollar powerhouse. The list of successes included Cyndi Lauper, Culture Club, Quiet Riot, Ozzy Osborne, REO Speedwagon, Survivor, Gloria Estefan, Stevie Ray Vaughn, Molly Hatchet, Heart, Luther Vandross, and the "King of Pop," Michael Jackson.
While at Epic, Frank oversaw the plans that helped create the largest selling album in music history with over 45 million sold worldwide. He was voted executive of the year for Epic Records, received over 80 gold and platinum awards, and was credited for taking Epic Records from the number fourteen label in the U.S. market to number two.
After this tremendous success, Mr. Dileo became Michael Jackson's manager directly responsible for managing all professional aspects of Michael Jackson's career relating to performances, film, commercials and videos. Mr. Dileo executive produced the full-length movie "Moonwalker" starring Michael Jackson. He wrote and executive produced three Pepsi-Cola commercials (including negotiating a landmark endorsement deal), and eight music videos including the Grammy winning video "Leave Me Alone."
Mr. Jackson decided to tour the world during the release of his "Bad" album while Mr. Dileo oversaw all aspects which, to date, became the largest grossing tour of all time. He also directed all aspects of the Jackson family's "Victory" tour of arenas, an unprecedented accomplishment for its time.
Mr. Dileo also managed the careers of Taylor Dayne, Jodeci, Laura Branigan, and Bon Jovi guitarist Richie Sambora, and has worked with Prince on several groundbreaking projects.
Mr. Dileo has since been a consultant to the entertainment industry, appearing personally in three major motion pictures. His film credits include GoodFellas, Wayne's World I & Wayne's World II and Moonwalker). Mr. Dileo has also appeared on many major and cable network shows as well as being quoted in the mainstream media and industry periodicals.
Mr. Dileo currently heads Dileo Entertainment Group, a music management company in Nashville, Tennessee.
About ValCom:
ValCom currently operates 200,000 square feet of production studios in Burbank, Ca. and Las Vegas, Nevada. ValCom has a film and television library of 143 movies and 10 television shows as well as an animation subsidiary located in Ireland. ValCom is a minority owner of a Television station in Palm Springs, Ca.
Based in Los Angeles, California, ValCom, Inc. is a diversified and vertically integrated, independent entertainment company. ValCom, Inc., through its operating divisions and subsidiaries, creates and operates full service facilities that accommodate film, television and commercial productions with its four divisions comprised of: studio, film and television, live theater production, and broadcast television. ValCom's clientele list consists of all of the majors such as MGM, Paramount Pictures, ABC, CBS, Sony, NBC, BET, MTV.
Contact:
Frank Dileo
615-244-9599
Investor Relations
Ten Associates, LLC
Tom Nelson
480-326-8577
Web Site: www.valcom.tv
Source: Market Wire (September 25, 2007 - 11:53 AM EST)
will look into it ... at a glance ... looking leveled off...hanging around bottom
Allwaysright...
I let my premium account laps.... no PMing for me. Still get them though.
Currently I dont. Know several that do who asked if they should sell after it dropped to .08 ... told them to hold. Based on chart saw it as a bottom play.... now just watching it for them and may play.......
I like ABVG and DKGR also watching STEM so want it to go below 2.00. been coming close. GNBT been a fav since 05 when I was loading around .80... Has a fair value of 1.50 which it hangs around. based on chart you can guess how I play it.
Take care. Hit me up anytime.
Sulkair
http://www.buyandhold.com/bh/en/resource_center/taxes/carlson4.html
Tax Tips for Stock and Fund Investors
Charles Carlson, CFA
Contributing Editor, Dow Theory Forecasts
Taxes have an insidious effect on your portfolio returns, especially over time. Every dime you pay Uncle Sam in taxes, such as capital-gains taxes or taxes on dividend income, is a dime that will never earn you any future returns. It's gone forever. Here are some ways to avoid Uncle Sam in your investment program:
* Avoid frequent trading -- One reason I like a buy-and-hold investment philosophy is that it is extremely tax friendly. In many cases, selling stock means incurring a tax liability if you have a gain in the stock. And depending on how long you've owned the stock and your tax bracket, your tax liability could be as much as 39.6 percent of your profit. You can lessen the impact of taxes on your investment returns by holding investments for at least 12 months, thus incurring the more favorable tax treatment when you sell.
* Stocks are usually better investments than other investment vehicles when it comes to avoiding Uncle Sam. With individual stocks, you control your tax destiny; you incur a tax liability only when you decide to sell the shares. With stocks, you can defer taxes indefinitely. You can even wipe out any tax liability on investments if you pass along the investments to your heirs when you die. That's because your heirs receive a "stepped-up" cost basis on stocks that they inherit. Unfortunately, you may not have a say over the tax issue with certain investment choices. If you're ambivalent between owning individual stocks and other investment derivatives, keep in mind the tax advantages of stocks.
* If you invest in mutual funds, make sure they are "tax friendly." One way to assess the "tax friendliness" of a mutual fund is to examine its "turnover ratio." This ratio measures the level of selling in the fund. A turnover ratio of 100 percent means that the fund manager turned over the entire portfolio once during that year. The lower the turnover ratio, the lower the amount of selling that is done in the portfolio, and the lower your potential tax hit. A number of mutual fund families are developing what they call "tax-efficient" funds. Characteristics of these funds include:
1. Infrequent selling of fund positions
2. Minimizing the taxable gain on sales by assigning the highest cost basis possible to the sold shares
3. Offsetting gains by selling fund holdings with losses
4. Favoring stocks with modest dividends, since dividends are taxed as ordinary income
When considering a "tax-friendly" fund, don't ignore index funds, which tend to be very tax friendly.
* Consider the tax-status of the particular investment account when deciding on investments. Retirement accounts, because they are tax preferenced, are probably better vehicles for holding less tax-friendly investments, such as mutual funds. Retirement accounts are also good vehicles for holding income-generating investments, such as bonds and dividend-paying stocks. Does this mean that you should never hold stocks in an IRA or 401(k) plan? Certainly not. However, it does mean that it's not a bad idea to weight your retirement portfolio a bit toward higher-yielding investments -- total-return stocks, balanced mutual funds, etc. -- in order to maximize the tax benefits. Also, by including mutual funds in a tax-preferenced account, you mitigate the effects of unwanted capital-gains distributions. Conversely, higher-growth potential investments, such as stocks, should be held outside of retirement accounts. In this way, you limit the tax bite by owning stocks (and being able to defer indefinitely capital-gains taxes) and have the ability to exploit losses.
* Avoid "avoidable" tax transactions. For example, before buying a mutual fund toward the end of the year, make sure the fund has already made its capital-gains distribution for that year. There's nothing more galling than buying a mutual fund, perhaps showing a loss on paper in the fund, yet having to pay taxes on a capital-gains distribution that you receive shortly after buying the fund. Most fund families will tell you the approximate date when a capital-gains distribution is planned. Other common taxable transactions to avoid include writing checks on your bond mutual fund (every time you do this, you incur a potential tax liability) and frequent switches between funds within the same mutual-fund family (switches constitute taxable transactions). Another tax mistake is putting tax-preferenced investments (such as municipal bonds) in tax-preferenced accounts, such as IRAs.
More about taxes:
Taxes 101
Investing With Uncle Sam's Money
Tax Tips for Stock and Fund Investors
Uncle Sam, Investment Partner
The price of oil surged above $83 a barrel on Friday morning, closing in on its record high of $83.90, before falling back a touch in afternoon action. Other commodity markets were also flirting with record territory Friday. Gold futures rose to a 28-year high topped $750 an ounce, while other precious metals like copper also rallied.
http://www.americanthinker.com/blog/2007/09/canadian_dollar_closes_above_u.html
Good Stuff!!
Greater China Media & Entertainment Corporation's 'Tough Guy' Completes Shooting
Tuesday September 25, 9:00 am ET
BEIJING, Sept. 25 /Xinhua-PRNewswire/ -- Greater China Media & Entertainment Corporation (OTC Bulletin Board: GCME - News), an integrated professional media and entertainment company, today announced that its new movie 'Tough Guy' has finished filming in China.
ADVERTISEMENT
'Tough Guy' was produced as a joint investment by GCME and Mega Vision Productions Limited, an entertainment group specializing in film productions. Total investment for 'Tough Guy' was approximately US$1 million. GCME will be entitled to 50% of profits generated from the movie.
Liu Ye stars as Lao San, a brave, down-to-earth veteran who fights for justice. This role is ground-breaking for handsome Liu Ye, who continues to impress by choosing roles that challenge him and advance his career. From simple "peasant-like" introverts, to bold schemers, Liu Ye's remarkable acting skills have not only garnered widespread public acclaim, but also the respect of international directors such as Stanley Kwan (Lan Yu), Chen Kaige (The Promise), Zhang Yimou (Curse of the Golden Flower) and John Woo (Blood Brothers) -- all of whom have widely praised his work and sought to include him in their major movie productions.
"We are pleased that Liu Ye has agreed to play Lao San, a unique character that is quite a change from his previous roles", stated Jake Wei, Chairman and CEO of Greater China Media and Entertainment Corporation. "This role will transform Liu's career and bring his work to the attention of critics and movie-lovers around the world."
About Greater China Media and Entertainment Corporation:
Greater China Media & Entertainment Corp. ("GCME" or the "Company"), is an integrated professional media and entertainment company involved in various areas including film and TV program production, management, promotion and distribution. The Company maintains its own film and television production center, promotion agency, audio-visual distribution company, digital network company, talent agency and sales and advertising agency, as a result of recent joint ventures. With its broad range of media and entertainment talents, the Company is capable of making films, TV programs and related projects on a large scale.
Joint ventures:
In June 2006, GCME signed and closed an Acquisition Agreement with Triumph Research Limited, which is a BVI company and party to a Joint Venture Agreement with Beijing Tangde International Film and Culture Co., Ltd. (Tangde), a Chinese company focused on producing TV programming and movies. The Company's public relations, media strategy, consulting and event management joint venture, Beijing Racemind HuaDing International Marketing Consultants Limited (Racemind HuaDing) was organized in 2006 and approved for business by the Beijing Administration for Industry in May 2007. The Company also signed an agreement with Beijing Star King Talent Agency to form a joint venture to carry on business as a talent agency.
Recent milestones:
Movie and television series production and distribution
-- Signed a production and distribution deal with Mega Vision Productions Limited for the new 'Tough Guy' movie.
-- Took delivery of its first script for its 'True Love' television series to be directed by famed director Wong Jing.
-- Signed a production and distribution deal for its 'Poor Dad, Rich Dad' television series with HuaYi Union Cultural Media Investment Company Limited. 'Poor Dad, Rich Dad' has finished shooting recently.
Racemind HuaDing
-- Signed service agreement with Siemens LTD. China's Transportation Systems group.
-- Provided public relations services to Beijing ShiChuang Environmental Protection Development Co., Ltd.
-- Organized Johnson & Johnson "Family Event".
-- Selected by Microsoft China as an approved public relations vendor, and arranged conferences, new product press releases and events.
For more information please visit the Company website at http://www.greaterchinamedia.com .
Forward-looking statements:
This report contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this report are forward-looking statements. Forward-looking statements involve risks and uncertainties including, but not limited to, economic and political factors; developments of the Chinese and North American markets and changes in regulatory matters; our business strategies and future plans of operations; the market acceptance and amount of sales of our products and services; our historical losses; the competitive environment within the industries in which we compete; and our ability to raise additional capital, currently needed for expansion.
The Company cautions that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements due to several important factors.
For more information, please contact:
Greater China Media & Entertainment Corp.
Jake Wei
Tel: +86-10-5921-2333
Source: Greater China Media & Entertainment Corporation
Can you post that on the web site company blog please......
other then the past relation ... no I am not worried about Dale.(good guy).. or downshire.. the point of my initial post was showing that unless it is public knowledge with the sec or an insider leak...anyone saying that they heard there is an investigation under way by the sec of a company or company's that have had association with said company is full of it and should be discounted.....
any way thats it.. remove or reinstate... I am happy with my investments in BNPD and others...
mkt_predictor the post was pertaining to BNPD as it was recommended by the IR who was paid:: BNPD 1,000,000 free trading shares for Investor Relations Work from JD Pulver and was also a past member of downshire ... if indeed they are look at by the SEC and found at some fault... will reflect upon BNPD's image of good or poor business decisions
If you would like I will edit previous post and add the BNPD to the post as i inferred the relation to BNPD and other like promoted company's ...
Morning Ca$h ... I agree .... ABVG needs to +++++ and today would be great.
Very nice... listening now....
click on the 10 year chart..........: http://investorshub.advfn.com/boards/quotes.asp?ticker=AAPL&qm_page=59156&qm_symbol=AAPL
and take into account this::
# Capital Change=shs increased by 2 for 1 split. Ex-date=06/21/2000. Rec date=05/19/2000. Pay date=06/20/2000.
# Capital Change=6-87 shs increased by 2 for 1 split
shs increased by 2 for 1 split
Ex-Date: Feb 28, 2005
and I would say yes an all time high..........
UR heres something for you to dig on.... dont have time right now.. but was on my mind...
"Kinross acquired the 90% interest in and became operator of the Julietta underground mine located in the Omsukchansk Region of the Magadan Oblast, Russia"
"The Kupol project is located in the Chukotka region"
http://www.kinross.com/
Governments on the WWW: Russian Federation
http://www.gksoft.com/govt/en/ru.html
"The mining claims are currently in production and lie in close proximity to properties owned by Kinross Gold Corporation.
ABVG .026 ABV Gold, Inc. Closes Acquisition of a 70% Interest in a Producing Gold Mine in Russia
MONTREAL, Sep 24, 2007 (MARKET WIRE via COMTEX) -- ABV Gold, Inc. (PINKSHEETS: ABVG) (FRANKFURT: AB8) is pleased to announce the acquisition of a 70% interest in a producing gold mine in Russia.
"ABV Gold, Inc. is pleased to announce that we have closed the acquisition of a 70% interest in a producing gold mine in Russia," reports Daniel Ryan, President of ABV Gold, Inc. "Narrow Galaxy Inc., a Russian holding company, owns mining license ABN#00363 and ABN#00362. We have agreed to buy a 70% interest in these mining licenses. The mining claims are currently in production and lie in close proximity to properties owned by Kinross Gold Corporation. The claim encompasses 33,995 square Km. The enormous land position gives us potential on the exploration front which complements the immediate prooduction upside."
"This acquisition will be key in creating value for ABV Gold, Inc. shareholders," added Mr. Ryan. "The fact that this project is in production is immediately beneficial to our shareholders. We acquired the project in a manner that would minimize dilution and maximize value. It is our intention to make this project into a multi million dollar producer. The reports and studies we have in hand give us confidence that we are getting into a great situation at a very modest price."
"In order to close the transaction we have agreed to issue 1,500,000 preferred A shares of ABV Gold, Inc. to Narrow Galaxy Inc. These shares have a par value of $1.00 USD and carry a rate of interest of 10%. The interest is only payable beginning January 1st, 2008," said Mr. Ryan. "It is our expectation to begin retiring these shares with cash flow from production in Q2 of 2008. The mine in question is open pit and has a been in production since 2003. We intend to report more comprehensive details on the property later this week."
About ABV Gold
ABV Gold is a publicly traded, junior mining-exploration company headquartered in Montreal, Canada. The company pursues the acquisition and development of mining properties known to contain significant mineral assets, principally uranium and/or gold. For additional information, please visit the corporate website at www.abvgoldinc.com.
Contact:
Daniel Ryan
President
dryan@abvgoldinc.com
1-514-448-2193
Dale Baeten
dale@midweststockconsultingllc.com
1-920-418-0153
Good start...............
I like how easy it moves......
picked up more today.... after our little correction last week.... if we do get news today .. will make for a very nice week....
the rest of the story.....::Trump Snubs Freelancer?
How ironic that Trump, whose very name conjures up unbridled wealth, is accused of not paying a lowly freelancer who writes for their magazine. Torey Marcus emailed FishbowlNY asking for help in fetching the $1,000 that is her due for an interview with Overstock CEO Patrick Byrne, which is up on their website. The story ran in the Spring 2007 issue.
Marcus' contract stated that there would be payment upon publication. Over a month aand a half after publication, Torey contacted the publisher's office about payment for the story. Michael Jacobson, the publisher, emailed Torey that payment would be ''processed 30 days from receipt of this E-mail.'' That was August 9th. Marcus emails FishbowlNY, ''Subsequent emails to Jacobson over the past few weeks have gone unanswered.''
According to Torey, a phone call to the assigning editor Jennifer Wysmuller was met with a ''the-number-you-have-reached-has-been-disconnected message.''
This is, to be sure, an interesting reflection on the vaunted Trump organization, no?
http://www.mediabistro.com/fishbowlny/
its possible.... really dislike the waiting .... have a good weekend....
Cool.. maybe we finally will be getting some were.... new site, new deals, new TA info... and so on.....
it was working this morning about 3 hours ago .... last I checked
keep getting "unable to connect" to http://www.abvgoldinc.com/ any one else seeing this? if it isnt just an issue I am having .. then we could be seeing the new web site VERY soon...
its not friday yet.....
interesting as the word spreads.....featured on http://www.audiostocks.com/index.php as well
haha ..... they are looking to become IR for DKGR as a 3rd party (imo) not novak..... Clayton is a director of DKGR no longer the ceo.. the relation of novak to VMHIF has nothing to do with claytons position with DKGR or there IR'ing
Explain how that is a conflict of interest.....
Nice......
Poor Dad, Rich Dad TV Series Wraps Up
BEIJING, Sept 18, 2007 /Xinhua-PRNewswire via COMTEX/ -- Greater China Media & Entertainment Corporation (OTC Bulletin Board: GCME) (GCME), an integrated professional media and entertainment company, today announced that the 'Poor Dad, Rich Dad' TV drama has wrapped up shooting in Australia.
'Poor Dad and Rich Dad' was created through a joint investment by GCME and Beijing Hua Yi Union Cultural Media Investment Company Limited, a professional media company renowned for its quality movie and TV products. Total investment for the show was approximately US$1.97 million. GCME will be entitled to 33% of profits generated from the series.
'Poor Dad and Rich Dad' is a story about the generation gap, family intimacy and the growing pains of youth. Lead actor Chen BaoGuo, a prominent and popular performer in both movies and television, has expressed his pleasure in working on the project with popular GCME signed actresses Tang XiaoXiao from Mainland China, and Yin Shin from Taiwan. In 'Poor Dad and Rich Dad', Tang XiaoXiao plays the daughter of Chen's friend, while Yin Shin performs the role of Chen's lover.
Tang XiaoXiao has appeared in a number of Chinese TV dramas since graduating from one of the most prestigious acting colleges in China, the Beijing Film Academy. Her prankish and adorable role in 'Poor Dad and Rich Dad' establishes her as the next big star of television and movies. Yin Shin, an exceptional actress who is well-known to the Chinese audience for her previous leading roles, delivers a breakthrough performance that showcases both her talent and her professionalism.
"In addition to the fabulous performances by some of our leading actors, audiences will find the spectacular Australian scenery and stunning camerawork to be a compelling and appropriate backdrop for this exceptional television series," said Mr. Wei, Chairman and CEO of Greater China Media & Entertainment Corporation. "We're very pleased at the quality of this program and we look forward to introducing viewers to these compelling characters."
About Greater China Media and Entertainment Corporation:
Greater China Media & Entertainment Corp. ("GCME" or the "Company") is an integrated professional media and entertainment company covering various areas including film and TV program production, management, promotion and distribution. The Company maintains its own film and television production center, promotion agency, audio-visual distribution company, digital network company, talent agency, and sales and advertising agency as a result of recent joint ventures. With its broad range of media and entertainment talents, the company is capable of making films, TV programs and related projects on a large scale.
Joint ventures:
In June 2006, GCME signed and closed an Acquisition Agreement with Triumph Research Limited, which is a BVI company and party to a Joint Venture Agreement with Beijing Tangde International Film and Culture Co., Ltd. (Tangde), a Chinese company focused on producing TV programming and movies. The Company's public relations, media strategy, consulting and event management joint venture, Beijing Racemind HuaDing International Marketing Consultants Limited (Racemind HuaDing) was organized in 2006 and approved for business by the Beijing Administration for Industry in May 2007. The Company also signed an agreement with Beijing Star King Talent Agency to form a joint venture to carry on business as a talent agency.
Recent milestones:
Movie and television series production and distribution
-- Promoted the film 'Tough Guy' at the 2007 China International Film & TV
Programs Exhibition
-- Signed a production and distribution deal with Mega Vision Productions
Limited for 'Tough Guy'.
-- Took delivery of its first script for its 'True Love' television series
to be directed by famed director Wong Jing
-- Signed a production and distribution deal for its 'Poor Dad, Rich Dad'
television series with HuaYi Union Cultural Media Investment Company
Limited
Racemind HuaDing
-- Provided public relations services for the 2007 Asia-Pacific Robot
Contest sponsored by CCTV, China's national television network
-- Designed and produced "Environmental Protection Park Green Law and
Service Brochure" for Beijing ShiChuang Environmental Protection
Development Co., Ltd.
-- Organized Siemens' "CRH3"project and its "Chinese Solutions for
offshore Shipbuilding Oil and Gas Press Briefing" press release
-- Organized Johnson & Johnson's "Family Event"
-- Selected by Microsoft China as an approved public relations vendor, and
arranged conferences, new product press releases and events
For more information please visit the Company website at http://www.greaterchinamedia.com.
Forward-looking statements:
This report contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this report are forward-looking statements. Forward-looking statements involve risks and uncertainties including, but not limited to, economic and political factors; developments of the Chinese and North American markets and changes in regulatory matters; our business strategies and future plans of operations; the market acceptance and amount of sales of our products and services; our historical losses; the competitive environment within the industries in which we compete; and our ability to raise additional capital, currently needed for expansion.
The Company cautions that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements due to several important factors.
For more information, please contact:
Greater China Media & Entertainment Corp.
Jake Wei
Phone: +86-10-5921-2333
SOURCE Greater China Media & Entertainment Corporation
URL: http://www.greaterchinamedia.com
www.prnewswire.com
1 million shares pushed us up 25% .... float mostly eaten up???